COMPASS THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
COMPASS THERAPEUTICS, INC. (CMPX) reported Share-based Payment Arrangement, Expense of $4.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.82M, a 72.77% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $5.07M, a 101.79% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.82M, a 18.45% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.24M, a 43.68% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $8.37M, a 2.24% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $8.56M, a 39.87% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $6.12M, a 14.82% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $5.33M, a 32.29% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.82M 10-Q · filed 2026-08-06 | $9.89M 10-Q · filed 2026-08-06 | $11.72M derived: sum of 3 quarters · filed 2026-08-06 | $12.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-05 | $6.90M derived: sum of 2 quarters · filed 2026-05-05 | $8.14M derived: sum of 3 quarters · filed 2026-05-05 | $10.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.06M derived: sum of 2 quarters · filed 2026-03-05 | $5.85M derived: sum of 3 quarters · filed 2026-08-06 | $8.37M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.24M 10-Q · filed 2025-11-05 | $4.03M derived: sum of 2 quarters · filed 2026-08-06 | $6.54M 10-Q · filed 2025-11-05 | $8.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.79M 10-Q · filed 2026-08-06 | $5.30M 10-Q · filed 2026-08-06 | $7.54M derived: sum of 3 quarters · filed 2026-08-06 | $9.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.51M 10-Q · filed 2026-05-05 | $4.75M derived: sum of 2 quarters · filed 2026-05-05 | $6.95M derived: sum of 3 quarters · filed 2026-05-05 | $9.07M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.44M derived: sum of 2 quarters · filed 2026-03-05 | $6.56M derived: sum of 3 quarters · filed 2026-03-05 | $8.56M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.20M 10-Q · filed 2025-11-05 | $4.32M derived: sum of 2 quarters · filed 2025-11-05 | $6.32M 10-Q · filed 2025-11-05 | $7.92M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.12M 10-Q · filed 2025-08-11 | $4.12M 10-Q · filed 2025-08-11 | $5.72M derived: sum of 3 quarters · filed 2025-08-11 | $7.35M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-08 | $3.60M derived: sum of 2 quarters · filed 2025-05-08 | $5.23M derived: sum of 3 quarters · filed 2025-05-08 | $6.86M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.23M derived: sum of 2 quarters · filed 2025-02-27 | $4.85M derived: sum of 3 quarters · filed 2025-02-27 | $6.12M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-12 | $3.25M derived: sum of 2 quarters · filed 2024-11-12 | $4.52M 10-Q · filed 2024-11-12 | $5.54M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.63M 10-Q · filed 2024-08-12 | $2.90M 10-Q · filed 2024-08-12 | $3.92M derived: sum of 3 quarters · filed 2024-08-12 | $5.21M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.27M 10-Q · filed 2024-05-13 | $2.29M derived: sum of 2 quarters · filed 2024-05-13 | $3.58M derived: sum of 3 quarters · filed 2024-05-13 | $5.02M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.31M derived: sum of 2 quarters · filed 2024-03-21 | $3.76M derived: sum of 3 quarters · filed 2024-03-21 | $5.33M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.29M 10-Q · filed 2023-11-09 | $2.73M derived: sum of 2 quarters · filed 2023-11-09 | $4.30M 10-Q · filed 2023-11-09 | $5.49M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.44M 10-Q · filed 2023-08-03 | $3.02M 10-Q · filed 2023-08-03 | $4.20M derived: sum of 3 quarters · filed 2023-08-03 | $5.19M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.57M 10-Q · filed 2023-05-04 | $2.76M derived: sum of 2 quarters · filed 2023-05-04 | $3.75M derived: sum of 3 quarters · filed 2023-05-04 | $4.70M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.17M derived: sum of 2 quarters · filed 2023-03-15 | $3.12M derived: sum of 3 quarters · filed 2023-03-15 | $4.03M 10-K · filed 2023-03-15 |
| 2021-09-30 | $987.00K 10-Q · filed 2022-11-09 | $1.94M derived: sum of 2 quarters · filed 2022-11-09 | $2.84M 10-Q · filed 2022-11-09 | $3.93M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $948.00K 10-Q · filed 2022-08-01 | $1.86M 10-Q · filed 2022-08-01 | $2.95M derived: sum of 3 quarters · filed 2022-08-01 | $5.48M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $948.00K 10-Q · filed 2022-05-09 | $2.00M derived: sum of 2 quarters · filed 2022-05-09 | $4.53M derived: sum of 3 quarters · filed 2022-05-09 | $4.72M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $3.59M derived: sum of 2 quarters · filed 2022-03-18 | $3.77M derived: sum of 3 quarters · filed 2022-03-18 | $4.02M 10-K · filed 2022-03-18 |
| 2020-09-30 | $2.54M 10-Q · filed 2020-11-09 | $2.72M derived: sum of 2 quarters · filed 2020-11-09 | $2.97M 10-Q · filed 2021-11-12 | $3.19M derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-06-30 | $183.00K 10-Q · filed 2020-08-13 | $430.00K 10-Q · filed 2021-08-16 | $656.00K derived: sum of 3 quarters · filed 2021-04-30 | $905.00K derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-03-31 | $247.00K 10-Q · filed 2021-04-30 | $473.00K derived: sum of 2 quarters · filed 2021-04-30 | $722.00K derived: sum of 3 quarters · filed 2021-04-30 | $907.00K derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $475.00K derived: sum of 2 quarters · filed 2021-03-05 | $660.00K derived: sum of 3 quarters · filed 2021-03-05 | $915.00K 10-K · filed 2021-03-05 |
| 2019-09-30 | $249.00K 10-Q · filed 2020-11-09 | $434.00K derived: sum of 2 quarters · filed 2020-11-09 | $689.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $185.00K 10-Q · filed 2020-08-13 | $440.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |